Forte Capital LLC ADV Trims Position in Novo Nordisk A/S (NYSE:NVO)

Forte Capital LLC ADV lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 35.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 42,278 shares of the company’s stock after selling 22,723 shares during the quarter. Forte Capital LLC ADV’s holdings in Novo Nordisk A/S were worth $3,637,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in NVO. International Assets Investment Management LLC lifted its stake in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $98,765,000. DAVENPORT & Co LLC raised its position in shares of Novo Nordisk A/S by 75.1% in the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after buying an additional 451,641 shares during the period. Wellington Management Group LLP purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $42,017,000. Finally, DSM Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 16.7% in the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock worth $172,678,000 after buying an additional 286,912 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.5 %

Shares of NYSE NVO opened at $83.79 on Friday. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The company has a market cap of $376.02 billion, a P/E ratio of 25.47, a P/E/G ratio of 0.88 and a beta of 0.45. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a fifty day moving average price of $86.39 and a 200 day moving average price of $108.48.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 21.88%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NVO. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.